Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are 18 years of age or older at the time of signing the consent form, regardless of gender.
- People who have been diagnosed with either triple-negative breast cancer (a type of breast cancer that lacks three specific receptors) or hormone receptor-positive, HER2-negative breast cancer (a type that responds to hormones but lacks a specific protein called HER2), confirmed by tissue or cell testing, where the cancer has spread, come back, or cannot be removed by surgery with the aim of curing it.
- People who are planned to receive the study drug SKB264, either on its own or combined with another treatment.
- People with triple-negative breast cancer who have received no more than 2 previous systemic (whole-body) anti-cancer treatments for their advanced or spread disease, or people with hormone receptor-positive, HER2-negative breast cancer who have received no more than 2 previous systemic anti-cancer treatments (not counting hormone-based therapies) for their advanced or spread disease.
- People who are willing to take part in the study, sign the consent form, and are able to follow the study requirements.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have or have had another type of cancer, unless it was a fully treated skin cancer (basal or squamous cell type) or cervical cancer caught very early, and people with any other prior cancer must have been cancer-free for at least 5 years.
- People who are currently taking part in another clinical trial that involves a treatment or intervention.
- People who are known to be allergic to the study drug or any of its ingredients.
- People who are pregnant or currently breastfeeding.
- People whose situation, in the opinion of the researchers, could interfere with assessing the study drug, affect participant safety, or affect the study results, or who the researchers otherwise consider unsuitable for the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-010-87787242
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to next treatment (TTNT) of SKB264 monotherapy or combination therapy in patients with unresectable locally advanced, recurrent or metastatic HER2-negative breast cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.